hamster
polyomaviru
hapyv
major
capsid
protein
base
chimer
viruslik
particl
vlp
carri
model
ctl
epitop
deriv
lymphocyt
choriomening
viru
lcmv
gener
yeast
examin
capabl
induc
ctl
respons
mice
chimer
vlp
effect
process
antigen
present
cell
vitro
vivo
induc
antigenspecif
cell
prolifer
mice
immun
vlp
without
adjuv
develop
effect
memori
cell
respons
fulli
partial
protect
lcmv
infect
moreov
aggress
growth
tumor
express
significantli
delay
mice
vivo
therefor
hapyv
vlp
harbor
ctl
epitop
attract
vaccin
candid
induct
insertspecif
ctl
immun
respons
recombin
viruslik
particl
vlp
icosahedr
rodlik
structur
compris
multipl
copi
one
viral
structur
protein
usual
similar
authent
virus
deriv
noninfecti
free
viral
genet
materi
review
see
pumpen
gren
contrast
exogen
antigen
usual
process
via
mhc
class
ii
pathway
nonrepl
antigen
vlp
abl
enter
mhc
class
pathway
main
pathway
cell
activ
crosspresent
keller
et
al
storni
bachmann
storni
et
al
probabl
due
macromolecular
structur
particul
natur
vlp
may
provid
altern
tool
improv
nonimmunogen
peptid
immunogen
due
repetit
surfac
epitop
viruslik
structur
capabl
induc
humor
andor
ctl
respons
review
see
pumpen
gren
member
viral
famili
test
put
vlp
carrier
fuse
peptid
interest
coat
protein
expos
surfac
assembl
vlp
modifi
vlp
shown
highli
immunogen
antigen
carrier
capabl
induc
strong
humor
immun
respons
insert
antigen
buonaguro
et
al
herbstkralovetz
et
al
kang
et
al
zvirblien
et
al
antigen
carri
vlp
abl
induc
ctl
respons
well
ding
et
al
lacass
et
al
correspond
author
tel
fax
email
address
agedv
ibtlt
gedvilait
howev
induct
strong
ctl
respons
vlp
administ
togeth
adjuvantlik
molecul
cpg
storni
et
al
hamster
polyomaviru
hapyv
major
capsid
protein
vlp
power
vehicl
antigen
transport
toler
insert
differ
size
origin
amino
acid
aa
long
certain
site
gedvilait
et
al
gedvilait
et
al
addit
hapyv
chimer
vlp
produc
yeast
induc
strong
insertspecif
humor
respons
without
adjuv
repres
use
tool
gener
monoclon
antibodi
desir
specif
zvirblien
et
al
hapyv
vlp
abl
trigger
matur
human
dendrit
cell
dc
product
stimul
cell
vitro
effici
vlp
polyomavirus
jcv
bkv
mpyv
gedvilait
et
al
interestingli
chimer
mous
polyomaviru
capsid
protein
base
vlp
harbor
tumor
antigen
shown
inhibit
tumor
growth
mous
model
andreasson
et
al
brinkman
et
al
contrast
inform
capac
hapyv
base
chimer
vlp
induc
effect
epitopespecif
ctl
immun
respons
vivo
still
miss
studi
investig
capac
hapyv
chimer
vlp
trigger
develop
effect
ctl
respons
use
well
establish
model
system
depend
ctl
immun
base
protect
viru
tumor
vivo
peptid
correspond
b
restrict
ctl
epitop
aa
residu
surfac
glycoprotein
lymphocyt
choriomening
viru
lcmv
chosen
model
antigen
pircher
et
al
base
sever
alreadi
publish
featur
strong
ctl
epitop
present
b
mhc
molecul
recogn
context
specif
cell
pircher
et
al
ii
allow
trace
cell
respons
normal
mice
iii
epitop
wide
use
tumorassoci
model
antigen
depend
tumor
cell
type
antigen
express
level
differ
tumor
specif
immun
function
character
cell
prime
kundig
et
al
prevostblondel
et
al
spontan
tumor
regress
prevostblondel
et
al
ignor
herman
et
al
ochsenbein
et
al
speiser
et
al
toler
induct
ochsenbein
et
al
chimer
vlp
gener
yeast
saccharomyc
cerevisia
use
studi
ctl
respons
mice
vitro
vivo
dna
manipul
perform
accord
standard
procedur
sambrook
russel
clone
express
entir
sequenc
yeast
cerevisia
select
posit
primari
structur
correspond
aa
residu
introduct
foreign
sequenc
describ
previous
gedvilait
et
al
sasnauska
et
al
oligonucleotid
duplex
encod
amino
acid
long
lcmv
ctl
peptid
fig
insert
sequenc
posit
fig
clone
express
cassett
yeast
vector
sasnauska
et
al
chimer
proteinencod
sequenc
confirm
dna
sequenc
procedur
use
vlp
gener
cerevisia
strain
deriv
purif
slightli
modifi
compar
one
describ
earlier
gedvilait
et
al
briefli
yeast
cell
cultur
glucos
galactos
contain
induct
medium
h
collect
centrifug
disrupt
french
press
db
buffer
mm
tri
mm
nacl
mm
cacl
mm
larg
ph
contain
mm
pmsf
proteoblock
tm
proteas
inhibitor
cocktail
fermenta
uab
vilniu
lithuania
vlp
purifi
ultracentrifug
sucros
gradient
g
h
follow
h
incub
dnasefre
rnase
fermenta
uab
vilniu
lithuania
ultracentrifug
g
h
cscl
gradient
gml
fraction
contain
purifi
protein
collect
pool
dialyz
pb
lyophil
store
c
use
purifi
vlp
examin
nucleic
acid
contamin
accord
protocol
describ
previous
sasnauska
et
al
dnarna
detect
prepar
protein
sampl
sdspage
western
blot
analysi
perform
accord
method
describ
previous
gedvilait
et
al
primari
antibodi
mab
dr
zvirblien
vilniu
lithuania
mice
serum
use
confirm
vlp
assembl
purifi
protein
place
carbon
coat
palladium
grid
sampl
stain
aqueou
uranyl
acet
solut
examin
morgagni
electron
microscop
fei
oregon
usa
synthet
peptid
kavynfatm
correspond
b
restrict
ctl
epitop
amino
acid
residu
lcmv
surfac
glycoprotein
purchas
biosyntan
gmbh
berlin
germani
origin
cystein
anchor
posit
lcmv
peptid
replac
methionin
aichel
et
al
lcmvwe
isol
use
studi
origin
obtain
r
zinkernagel
zurich
switzerland
lcmvwe
cultiv
b
fibrosarcoma
cell
line
use
dmem
supplement
mm
lglutamin
penicillin
streptomycin
fc
mice
infect
iv
pfu
viral
titer
determin
use
cell
line
describ
battegay
et
al
statist
signific
viru
challeng
experi
calcul
use
wilcoxon
mannwhitney
test
mice
obtain
breed
stock
friedrichloeffl
institut
fli
germani
transgen
b
mice
line
carri
tcr
specif
amino
acid
epitop
lcmv
glycoprotein
aichel
et
al
purchas
hp
pircher
freiburg
germani
mice
sex
use
kept
spf
condit
anim
facil
fli
anim
experi
carri
accord
institut
guidelin
permiss
nation
author
tumor
experi
fibrosarcoma
tumor
cell
use
blohm
et
al
cell
deriv
parent
tumor
cell
gene
transfect
use
lcmv
minigen
prevostblondel
et
al
cell
cultur
dmem
high
glucos
supplement
fc
mm
lglutamin
penicillin
streptomycin
paa
laboratori
gmbh
austria
transfect
cell
addit
gml
select
gibco
invitrogen
uk
tumor
anim
trial
mice
encod
ear
tag
elimin
subject
bia
inject
tumor
cell
l
pb
flank
tumor
size
measur
calip
independ
two
person
blind
random
fashion
calcul
product
bisect
tumor
diamet
mice
bear
tumor
diamet
mm
kill
accord
anim
care
regul
experi
finish
mice
decod
result
analyz
cell
stain
flow
cytometri
perform
min
c
fac
buffer
pb
contain
fc
nan
cell
analyz
facsort
flow
cytomet
bd
bioscienc
usa
use
cellquestpro
softwar
cytometri
analysi
follow
mab
use
biotin
conjug
antimous
integrin
ax
clone
stain
fitc
pe
conjug
streptavidin
fitc
conjug
antimous
ia
b
clone
fitc
conjug
antimous
clone
fitc
conjug
antimous
clone
pure
rat
antimous
stain
pe
conjug
donkey
antirat
igg
h
l
fitc
conjug
antimous
clone
mab
purchas
bd
pharmingen
protocol
gener
mous
bone
marrow
deriv
dc
ident
use
lutz
et
al
immatur
dc
cellswel
incub
h
plate
mlwell
gml
vlp
construct
untreat
cell
serv
neg
control
immunophenotyp
matur
analysi
puls
dc
sampl
h
stain
fac
analysi
specif
antibodi
mous
mhcii
molecul
describ
singl
cell
suspens
mous
spleen
prepar
cell
prolifer
assay
stain
cfse
accord
manufactur
instruct
peptid
stimul
cfselabel
spleen
cell
stimul
peptid
final
concentr
dmem
media
fc
penicillinstreptomycin
plate
concentr
cellsml
unstimul
spleen
cell
serv
neg
control
stimul
dc
dc
puls
either
hapyv
chimer
vlp
describ
cfselabel
spleen
cell
cocultiv
variabl
puls
dc
plate
ratio
splenocyt
dcsml
c
splenocyt
incub
pb
immatur
dc
serv
neg
control
splenocyt
stimul
peptid
use
posit
control
tcrtg
mous
splenocyt
restimul
dc
dc
puls
vlp
describ
earlier
collect
place
plate
togeth
tcrtg
mous
cfselabel
splenocyt
splenocyt
dcsml
neg
control
splenocyt
incub
pb
posit
control
splenocyt
stimul
peptid
use
addit
neg
control
splenocyt
stimul
immatur
dc
dc
puls
peptid
use
addit
posit
control
prolifer
cell
determin
day
stimul
cfselabel
spleen
cell
label
pe
conjug
antimous
antibodi
analyz
flow
cytometri
live
cell
gate
cell
percentag
prolifer
cell
identifi
low
cfse
level
determin
cell
prolifer
result
compar
use
student
ttest
valu
p
consid
statist
signific
chimer
hapyv
vlp
lcmv
epitop
fig
insert
hapyv
posit
fig
accordingli
gedvilait
et
al
produc
heterolog
synthesi
yeast
cerevisia
gener
protein
expect
molecular
mass
kda
confirm
coomassi
brilliant
blue
stain
sdspage
yeast
lysat
western
blot
analysi
use
hapyv
mab
fig
chimer
protein
solubl
authent
hapyv
yield
fusion
protein
purif
mgg
yeast
cell
fusion
protein
assembl
vlp
similar
unmodifi
vlp
polyomavirustyp
diamet
nm
fig
immunogen
model
cell
epitop
present
chimer
vlp
studi
cocultiv
experi
complet
splenocyt
transgen
b
mice
carri
tcr
specif
amino
acid
epitop
lcmv
glycoprotein
aichel
et
al
stimul
vlp
peptid
alon
neg
control
splenocyt
treat
pb
chimer
vlp
abl
stimul
mous
deriv
cell
cell
almost
effect
peptid
alon
fig
b
stimulatori
effect
vlp
similar
peptid
stimul
vlp
around
cell
compar
less
cell
prolifer
observ
neg
control
vlp
without
insert
abl
stimul
cell
confirm
stimulatori
effect
chimer
hapyv
vlp
determin
cell
vlp
use
induct
dc
matur
vlppuls
dc
use
stimul
specif
cell
vitro
fig
prolifer
cell
vitro
cfselabel
splenocyt
label
pe
conjug
antimous
antibodi
day
stimul
analyz
flow
cytometri
live
cell
gate
cell
percentag
prolifer
cell
identifi
low
cfse
level
determin
flow
cytometri
data
one
repres
experi
cfselabel
mous
splenocyt
stimul
peptid
pb
vlp
vlp
shown
better
visual
evalu
statist
signific
data
independ
experi
mice
per
group
use
experi
summar
diagram
b
valu
shown
mean
sd
differ
statist
signific
p
label
ns
signific
ttest
c
cfselabel
splenocyt
mous
mous
neg
control
stimul
dc
treat
gml
vlp
splenocyt
dcsml
pb
untreat
dc
use
neg
control
peptid
dc
puls
peptid
use
posit
control
percentag
prolifer
cell
better
visual
evalu
statist
signific
shown
diagram
valu
two
independ
experi
mice
per
group
use
experi
shown
mean
sd
differ
statist
signific
p
label
ns
ttest
first
bone
marrow
deriv
dc
mice
mhcii
cell
cocultiv
empti
carrier
vlp
lp
pb
h
express
costimulatori
molecul
upregul
follow
matur
cell
stimul
either
vlp
lp
howev
observ
cell
treat
pb
dc
matur
effici
compar
examin
vlp
data
shown
second
vlppuls
dc
abl
stimul
prolifer
cell
mice
vitro
contrast
unpuls
dc
fig
strong
specif
prolifer
cell
mice
detect
compar
weak
nonspecif
prolifer
cell
mice
dc
treat
chimer
vlp
stimul
cell
time
stronger
dc
incub
empti
carrier
vlp
significantli
stronger
stimul
cell
detect
use
vlppuls
dc
compar
vlptreat
dc
effect
vlppuls
dc
strong
stimul
use
peptidepuls
dc
peptid
potenti
chimer
vlp
induc
cell
respons
verifi
cell
prolifer
assay
intracellular
measur
use
splenocyt
mice
vaccin
differ
vlp
week
immun
lcmv
challeng
vlp
immun
mice
also
perform
cell
prolifer
assay
confirm
vaccin
mice
vlp
gener
detect
cell
respons
prolifer
cell
vlp
immun
mice
restimul
peptid
twice
stronger
mice
immun
empti
vlp
time
weaker
prolifer
cell
mice
infect
lcmv
fig
splenocyt
vlp
immun
mice
restimul
peptid
h
unabl
produc
notabl
amount
intracellular
compar
high
level
produc
splenocyt
lcmv
immun
control
mice
data
shown
find
whether
induc
cell
respons
provid
protect
viral
infect
vivo
mice
immun
vlp
without
adjuv
challeng
lcmv
week
immun
control
lcmv
immun
mice
challeng
lcmv
well
high
viru
titer
found
mice
mice
vaccin
empti
carrier
vlp
fig
reduc
viru
titer
compar
vlp
immun
mice
measur
mice
immun
vlp
mice
immun
vlp
lcmv
could
detect
lcmv
immun
mice
mice
immun
vlp
mice
immun
vlp
fig
indic
singl
immun
chimer
vlp
without
adjuv
gener
ctl
respons
fulli
protect
partial
mice
lcmv
infect
investig
capabl
memori
cell
vlp
immun
mice
lyse
tumor
cell
pb
neg
control
immun
mice
inject
fibrosarcoma
cell
suspens
parallel
vlp
immun
mice
inject
cell
suspens
parent
cell
line
express
control
respons
tumor
antitumor
protect
capac
investig
time
cours
measur
tumor
progress
respons
tumor
vlp
immun
mice
fig
similar
respons
pbstreat
control
mice
tumor
growth
progress
tumor
pbstreat
control
mice
fig
parent
tumor
mice
immun
vlp
fig
reach
size
mm
day
vlpstreat
mice
day
vlpstreat
mice
post
tumor
inject
contrast
prophylact
immun
vlp
partli
protect
mice
tumor
growth
vlp
immun
mice
vlp
immun
mice
mice
immun
empti
carrier
vlp
compar
control
mice
develop
tumor
mm
size
day
fig
vaccin
mice
chimer
vlp
slightli
stronger
effect
tumor
growth
immun
empti
carrier
day
later
day
tumor
mice
immun
carrier
vlp
bigger
mm
reach
mm
size
mice
time
mice
immun
vlp
accordingli
tumor
smaller
mm
mice
develop
tumor
bigger
mm
mice
immu
nize
empti
carrier
vlp
tumor
reach
size
mm
day
group
mice
immun
vlp
mice
tumor
size
smaller
mm
day
moreov
mice
immun
vlp
stay
free
tumor
whole
experi
hapyv
vlp
use
therapeut
purpos
mice
bear
solid
tumor
day
post
tumor
inocul
tumor
reach
size
around
mm
mice
inject
iv
g
vlp
empti
carrier
pb
neg
control
vlp
inject
repeat
three
time
day
wherea
control
mice
tumor
grew
progress
day
reach
size
mm
mice
vlpstreat
mice
respond
therapi
fig
tumor
progress
arrest
tumor
growth
delay
observ
mice
group
receiv
vlp
therapi
immedi
first
inject
vlp
effect
slightli
differ
mice
treat
empti
carrier
vlp
mice
inject
vlp
tumor
grow
slower
control
mice
progress
except
one
mice
tumor
size
regress
seen
start
day
contrast
vlp
inject
induc
transient
tumor
growth
arrest
regress
similar
tumor
regress
pattern
observ
lcmv
infect
mice
prevostblondel
et
al
day
tumor
reach
size
mm
mice
treat
vlp
half
mice
inject
vlp
despit
strong
initi
vlpinduc
therapeut
effect
tumor
grew
progress
end
experi
humor
immun
respons
induc
immun
vlp
studi
mice
mice
per
group
serum
sampl
immun
mice
analyz
presenc
antibodi
chimer
vlp
day
first
second
third
immun
serum
four
immun
mice
antibodi
detect
enzym
immunoassay
start
first
immun
data
shown
confirm
western
blot
use
serum
collect
third
immun
fig
presenc
antibodi
serum
verifi
flow
cytometr
analysi
seratr
cell
express
cell
surfac
parent
cell
without
neg
control
serum
mice
show
posit
reaction
mice
develop
antibodi
peptid
start
second
immun
fig
mous
fail
develop
specif
antibodi
immun
vlp
data
shown
hapyv
vlp
demonstr
great
capac
epitop
display
system
gedvilait
et
al
gedvilait
et
al
excel
stimul
antibodi
product
zvirblien
et
al
human
dc
matur
vitro
dorn
et
al
howev
much
known
capabl
induc
ctl
immun
respons
vivo
thu
present
studi
analyz
potenti
hapyv
vlp
carrier
ctl
epitop
induc
effect
ctl
immun
respons
mice
unlik
peptid
chimer
vlp
process
dc
correct
antigen
present
bind
mhc
class
molecul
stimul
cell
nevertheless
induc
dc
matur
stimul
mous
splenocyt
vitro
effect
peptid
fig
b
moreov
vlp
puls
dc
abl
stimul
cell
vitro
much
strongli
peptidepuls
dc
peptid
without
dc
fig
result
clearli
demonstr
ctl
epitop
insert
hapyv
vlp
effici
process
crosspres
dc
like
nonrepl
vlp
keller
et
al
ruedl
et
al
storni
bachmann
storni
et
al
prolifer
cell
spleen
vlp
immun
mice
clearli
indic
cell
abl
recogn
antigen
furthermor
lcmv
challeng
tumor
experi
allow
us
assess
abil
vaccin
mice
elimin
express
cell
address
directli
cell
function
vivo
known
lcmv
infect
vivo
exclus
control
cell
absenc
viru
elimin
reflect
absenc
cytotox
cell
activ
bachmann
immun
chimer
vlp
without
adjuv
induc
protect
immun
respons
mice
mice
fulli
mice
partial
protect
lcmv
challeng
fig
suggest
effect
insertspecif
cell
induct
vivo
vlp
abl
stimul
effect
long
last
ctl
respons
vivo
especi
without
addit
adjuv
ding
et
al
lacass
et
al
martinez
et
al
interestingli
immun
chimer
hepat
b
core
ag
vlp
harbor
lcmv
peptid
fulli
protect
mice
lcmv
challeng
infect
appli
cpgrich
dna
show
effect
ctl
immun
respons
gener
vlp
also
use
aggress
tumor
model
lcmv
immun
mice
tumor
cell
fulli
reject
howev
lcmv
therapi
temporarili
elimin
tumor
final
tumor
escap
variant
appear
blohm
et
al
mice
vaccin
chimer
vlp
challeng
tumor
tumor
growth
delay
compar
mice
inject
pb
mean
memori
ctl
activ
fig
capabl
hapyv
vlp
induc
effect
ctl
respons
mice
support
also
therapeut
effect
tumor
fig
cell
activ
vlp
abl
identifi
elimin
inocul
tumor
cell
suspens
also
solid
tumor
cell
vivo
situat
howev
weaker
antitumor
effect
induc
vlp
compar
lcmvinduc
antitumor
effect
blohm
et
al
could
result
product
defici
splenocyt
stimul
vlp
known
seem
effector
molecul
tumor
model
blohm
et
al
surprisingli
immun
empti
vlp
show
extent
protect
antitumor
effect
cell
activ
vivo
induc
empti
vlp
effici
activ
observ
chimer
vlp
clearli
detect
might
possibl
inject
vlp
induc
mice
nonspecif
activ
immun
system
turn
respons
antitumor
effect
howev
note
vlp
stimulatori
effect
cell
vitro
fig
b
furthermor
prophylact
immun
vlp
clearli
delay
tumor
growth
effect
parent
tumor
cell
line
growth
mice
fig
b
thu
like
vlp
induc
activ
crossreact
memori
cell
known
tcr
contact
residu
peptid
present
mhc
molecul
requir
activ
tcr
cell
toler
certain
amino
acid
substitut
peptid
sequenc
therefor
antigen
specif
memori
cell
crossreact
differ
epitop
deriv
either
relat
antigen
total
unrel
one
exampl
crossreact
tcell
respons
involv
complet
unrel
virus
lcmv
vaccinia
viru
kim
et
al
influenza
viru
hiv
acierno
et
al
human
papilloma
viru
coronaviru
nilg
et
al
report
result
demonstr
effici
antibodi
respons
vlp
mice
inhibit
ctl
respons
although
one
report
vlpspecif
antibodi
neg
influenc
antigen
present
impair
induct
protect
immun
respons
da
silva
et
al
sever
studi
describ
specif
tcell
respons
nonrepl
vaccin
rather
improv
reduc
presenc
specif
antibodi
den
hann
bevan
kalergi
ravetch
ruedl
et
al
specif
antibodi
may
facilit
ctl
activ
enhanc
opson
vlp
lead
stronger
antigen
present
ctl
activ
presenc
specif
antibodi
could
advantag
enhanc
specif
ctl
respons
induc
chimer
vlp
conclus
vlp
well
process
crosspres
antigen
present
cell
insertspecif
cell
vlpsinduc
ctl
respons
protect
therapeut
capac
inhibit
b
cellmedi
immun
reaction
result
demonstr
potenti
chimer
hapyv
vlp
carrier
ctl
epitop
suitabl
induct
ctl
immun
respons
desir
antigen
